keyword
MENU ▼
Read by QxMD icon Read
search

Crohn's:8

keyword
https://www.readbyqxmd.com/read/28225427/race-differences-in-initial-presentation-early-treatment-and-1-year-outcomes-of-pediatric-crohn-s-disease-results-from-the-improvecarenow-network
#1
Jennifer L Dotson, Michele Cho, Josh Bricker, Michael D Kappelman, Deena J Chisolm, Gitit Tomer, Wallace V Crandall
BACKGROUND: Racially disparate care has been shown to contribute to suboptimal health care outcomes for minorities. Using the ImproveCareNow network, we investigated differences in management and outcomes of pediatric patients with Crohn's disease at diagnosis and 1-year postdiagnosis. METHODS: ImproveCareNow is a learning health network for pediatric inflammatory bowel disease. It contains prospective, longitudinal data from outpatient encounters. This retrospective study included all patients with Crohn's disease ≤21 years, September 2006 to October 2014, with the first recorded encounter ≤90 days from date of diagnosis and an encounter 1 year ±60 days...
February 20, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28221248/early-transcriptomic-changes-in-the-ileal-pouch-provide-insight-into-the-molecular-pathogenesis-of-pouchitis-and-ulcerative-colitis
#2
Yong Huang, Sushila Dalal, Dionysios Antonopoulos, Nathaniel Hubert, Laura H Raffals, Kyle Dolan, Christopher Weber, Jeannette S Messer, Bana Jabri, Albert Bendelac, A Murat Eren, David T Rubin, Mitch Sogin, Eugene B Chang
BACKGROUND: Ulcerative colitis (UC) only involves the colonic mucosa. Yet, nearly 50% of patients with UC who undergo total proctocolectomy with ileal pouch anal anastomosis develop UC-like inflammation of the ileal pouch (pouchitis). By contrast, patients with familial adenomatous polyposis (FAP) with ileal pouch anal anastomosis develop pouchitis far less frequently. We hypothesized that pathogenic events associated with the development of UC are recapitulated by colonic-metaplastic transcriptomic reprogramming of the UC pouch...
March 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28216978/role-of-capsule-endoscopy-in-suspected-celiac-disease-a-european-multi-centre-study
#3
Marisol Luján-Sanchis, Enrique Pérez-Cuadrado-Robles, Javier García-Lledó, José-Francisco Juanmartiñena Fernández, Luca Elli, Victoria-Alejandra Jiménez-García, Juan Egea-Valenzuela, Julio Valle-Muñoz, Cristina Carretero-Ribón, Ignacio Fernández-Urién-Sainz, Antonio López-Higueras, Noelia Alonso-Lázaro, Mileidis Sanjuan-Acosta, Francisco Sánchez-Ceballos, Bruno Rosa, Santiago González-Vázquez, Federica Branchi, Lucía Ruano-Díaz, César Prieto-de-Frías, Vicente Pons-Beltrán, Pilar Borque-Barrera, Begoña González-Suárez, Sofía Xavier, Federico Argüelles-Arias, Juan-Manuel Herrerías-Gutiérrez, Enrique Pérez-Cuadrado-Martínez, Javier Sempere-García-Argüelles
AIM: To analyze the diagnostic yield (DY), therapeutic impact (TI) and safety of capsule endoscopy (CE). METHODS: This is a multi-centre, observational, analytical, retrospective study. A total of 163 patients with suspicion of celiac disease (CD) (mean age = 46.4 ± 17.3 years, 68.1% women) who underwent CE from 2003 to 2015 were included. Patients were divided into four groups: seronegative CD with atrophy (Group-I, n = 19), seropositive CD without atrophy (Group-II, n = 39), contraindication to gastroscopy (Group-III, n = 6), seronegative CD without atrophy, but with a compatible context (Group-IV, n = 99)...
January 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28214210/pathologic-features-of-colorectal-carcinomas-associated-with-crohn-s-disease-in-korean-population
#4
Jiyoon Kim, Ho-Su Lee, Sang Hyoung Park, Suk-Kyun Yang, Byong Duk Ye, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Yong Sik Yoon, Chang Sik Yu, Jihun Kim
BACKGROUND: Colorectal cancer (CRC) has been known to complicate Crohn's disease (CD). Several reports in Western population revealed that CRC in CD were characterized by much younger onset and equal distribution of tumors along the entire colon. However, clinicopathologic features of CD-associated CRC in Korean population have not been well documented yet. METHODS: Among 2968 Korean CD patients, 16 patients (0.54%) were found to develop CRC during follow up. We reviewed clinicopathologic features of the 16 CRC patients...
December 21, 2016: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28211593/higher-infliximab-trough-levels-are-associated-with-perianal-fistula-healing-in-patients-with-crohn-s-disease
#5
A J Yarur, V Kanagala, D J Stein, F Czul, M A Quintero, D Agrawal, A Patel, K Best, C Fox, K Idstein, M T Abreu
BACKGROUND: Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn's disease, even though some patients do not benefit from therapy. AIM: To assess the correlation between perianal fistula healing and trough levels of infliximab. METHODS: In this cross-sectional study, we identified patients with Crohn's disease who had perianal fistulas and were treated with infliximab for at least 24 weeks. We excluded patients who underwent a faecal diversion procedure or proctectomy...
February 17, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28210083/incidental-adenocarcinoma-in-patients-undergoing-surgery-for-stricturing-crohn-s-disease
#6
Ivan Kristo, Stefan Riss, Stanislaus Argeny, Svenja Maschke, Praminthra Chitsabesan, Anton Stift
AIM: To evaluate frequency and clinical course of incidental adenocarcinoma in patients with stricturing Crohn's disease (CD). METHODS: In this study, consecutive patients, who were operated on for stricturing CD between 1997-2012, were included at an academic tertiary referral center. Demographic data and clinical course were obtained by an institutional database and individual chart review. Besides baseline characteristics, intraoperative findings and CD related history were also recorded...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28209624/tofacitinib-for-induction-and-maintenance-therapy-of-crohn-s-disease-results-of-two-phase-iib-randomised-placebo-controlled-trials
#7
Julian Panés, William J Sandborn, Stefan Schreiber, Bruce E Sands, Séverine Vermeire, Geert D'Haens, Remo Panaccione, Peter D R Higgins, Jean-Frederic Colombel, Brian G Feagan, Gary Chan, Michele Moscariello, Wenjin Wang, Wojciech Niezychowski, Amy Marren, Paul Healey, Eric Maller
OBJECTIVE: Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and maintenance treatment in patients with moderate-to-severe Crohn's disease (CD). DESIGN: We conducted two randomised, double-blind, placebo-controlled, multicentre phase IIb studies. Adult patients with moderate-to-severe CD were randomised to receive induction treatment with placebo, tofacitinib 5 or 10 mg twice daily for 8 weeks...
February 16, 2017: Gut
https://www.readbyqxmd.com/read/28208008/disability-due-to-inflammatory-bowel-disease-is-correlated-with-drug-compliance-disease-activity-and-quality-of-life
#8
Jin Young Yoon, Jeong Eun Shin, Sang Hyoung Park, Dong Il Park, Jae Myung Cha
Background/Aims: The inflammatory bowel disease disability index (IBD-DI) was recently developed for IBD to assess the functional consequences and disease burden. We applied the IBD-DI to a Korean population and identified predictive factors influencing IBD-related disability. Methods: Between March and August 2015, 322 consecutive patients with IBD were prospectively recruited. Patients completed the IBD-DI questionnaire and Crohn's and Ulcerative Colitis Questionnaire (CUCQ-8) for assessing quality of life...
February 17, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28205051/impact-of-preoperative-steroid-or-immunosuppressant-use-on-short-term-outcomes-following-colectomy-in-crohn-s-disease-patients
#9
N Valizadeh, A C A Murray, K Suradkar, A Al-Mazrou, R P Kiran
BACKGROUND: Evaluating the impact of steroid or immunosuppressants (SI) therapy prior to colectomy in Crohn's disease (CD) patients on postoperative septic and colectomy-specific outcomes using the American College of Surgeons (ACS)-National Surgical Quality Improvement Program (NSQIP)-targeted colectomy database. METHODS: All CD patients undergoing colectomy were retrieved from the 2012-2013 NSQIP-targeted database. Thirty-day postoperative outcomes were compared for patients who were on steroids or immunosuppressants (SI) within the 30 days prior to colectomy to the others using univariable and multivariable analyses...
February 15, 2017: Techniques in Coloproctology
https://www.readbyqxmd.com/read/28195851/maternal-infections-that-would-warrant-antibiotic-use-antepartum-or-peripartum-are-not-a-risk-factor-for-the-development-of-ibd-a-population-based-analysis
#10
Charles N Bernstein, Charles Burchill, Laura E Targownik, Harminder Singh, Jean Eric Ghia, Leslie L Roos
BACKGROUND: We aimed to determine whether maternal antenatal or perinatal infections (and thereby use of antibiotics) increase the risk of developing inflammatory bowel disease (IBD) in their offspring. METHODS: The University of Manitoba IBD Epidemiology Database contains records of all Manitobans diagnosed with IBD from 1984 to 2010. Each individual with IBD is matched to 10 controls. Subjects' medical system contacts are identified using a unique deidentified personal health identification number...
February 10, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28194815/peristomal-psoriasis
#11
C Marshall, S Woodmansey, C C Lyon
BACKGROUND: Psoriasis is a common skin condition, affecting 1.3-2.2% of the population. The prevalence of psoriasis has previously been reported as 11.2% in patients with Crohn disease (CD) and 5.7% in patients with ulcerative colitis. AIM: To assess the prevalence of psoriasis around stoma sites and identify the most effective treatment. METHODS: A departmental database of all patients attendings stoma clinic was accessed between 1 May 2003 and 15 October 2015...
February 13, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28187201/patient-self-reported-concerns-in-inflammatory-bowel-diseases-a-gender-specific-subjective-quality-of-life-indicator
#12
Valérie Pittet, Carla Vaucher, Florian Froehlich, Bernard Burnand, Pierre Michetti, Michel H Maillard
BACKGROUND: Patient-reported disease perceptions are important components to be considered within a holistic model of quality of care. Gender may have an influence on these perceptions. We aimed to explore gender-specific concerns of patients included in a national bilingual inflammatory bowel disease cohort. METHODS: Following a qualitative study, we built a questionnaire comprising 37 items of concern. Answers were collected on a visual analog scale ranging from 0 to 100...
2017: PloS One
https://www.readbyqxmd.com/read/28178003/efficacy-and-safety-of-vedolizumab-for-induction-of-remission-in-inflammatory-bowel-disease-the-israeli-real-world-experience
#13
Uri Kopylov, Yulia Ron, Irit Avni-Biron, Benjamin Koslowsky, Matti Waterman, Saleh Daher, Bella Ungar, Henit Yanai, Nitsan Maharshak, Ofer Ben-Bassat, Lev Lichtenstein, Ariella Bar-Gil Shitrit, Eran Israeli, Doron Schwartz, Eran Zittan, Rami Eliakim, Yehuda Chowers, Shomron Ben-Horin, Iris Dotan
BACKGROUND: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn's disease (CD). The aim of this study was to examine the "real world" efficacy and safety of VDZ in a large national patient cohort. METHODS: Patients with inflammatory bowel disease treated with VDZ were prospectively followed for 14 weeks. Patients who completed the induction protocol (week 0/2/6/14) or discontinued the treatment before week 14 for adverse events (AEs) or primary nonresponse were included...
February 7, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28170448/genome-wide-analysis-identifies-colonic-genes-differentially-associated-with-serum-leptin-and-insulin-concentrations-in-c57bl-6j-mice-fed-a-high-fat-diet
#14
Sung-Eun Kim, Jinsil Choo, Joon Yoon, Jae Ryang Chu, Yun Jung Bae, Seungyeoun Lee, Taesung Park, Mi-Kyung Sung
Obesity-induced chronic inflammation is known to increase the risk of ulcerative colitis, Crohn's disease, and colorectal cancer. Accumulating evidence suggests that leptin and insulin are key molecules linking obesity with diseases of the lower intestine. Here, we identified serum phenotype-associated genes in the colon of diet-induced obese mice as early biomarkers of obesity-associated colonic diseases. C57BL/6J mice were fed with either normal diet (ND, 15% of fat calories) or high-fat diet (HFD, 45% of fat calories) for 8 weeks...
2017: PloS One
https://www.readbyqxmd.com/read/28168575/efficacy-of-mesenchymal-stromal-cells-for-fistula-treatment-of-crohn-s-disease-a-systematic-review-and-meta-analysis
#15
REVIEW
Yantian Cao, Zhen Ding, Chaoqun Han, Huiying Shi, Lianlian Cui, Rong Lin
BACKGROUND AND AIM: The introduction of mesenchymal stromal cells (MSCs) has changed the management of Crohn's fistula, while it remains controversial. The aim of this study was to provide an overview of efficacy and optimum state of MSCs treatment on Crohn's fistula. METHODS: Studies reporting MSCs treatment on Crohn's fistula were searched and included. A fixed-effects model was used to assess the efficacy of MSCs, and outcomes of healing and recurrence were used to evaluate the best states of MSCs intervention...
February 6, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28166214/dense-genotyping-of-immune-related-loci-implicates-host-responses-to-microbial-exposure-in-beh%C3%A3-et-s-disease-susceptibility
#16
Masaki Takeuchi, Nobuhisa Mizuki, Akira Meguro, Michael J Ombrello, Yohei Kirino, Colleen Satorius, Julie Le, Mary Blake, Burak Erer, Tatsukata Kawagoe, Duran Ustek, Ilknur Tugal-Tutkun, Emire Seyahi, Yilmaz Ozyazgan, Inês Sousa, Fereydoun Davatchi, Vânia Francisco, Farhad Shahram, Bahar Sadeghi Abdollahi, Abdolhadi Nadji, Niloofar Mojarad Shafiee, Fahmida Ghaderibarmi, Shigeaki Ohno, Atsuhisa Ueda, Yoshiaki Ishigatsubo, Massimo Gadina, Sofia A Oliveira, Ahmet Gül, Daniel L Kastner, Elaine F Remmers
We analyzed 1,900 Turkish Behçet's disease cases and 1,779 controls genotyped with the Immunochip. The most significantly associated SNP was rs1050502, a tag SNP for HLA-B*51. In the Turkish discovery set, we identified three new risk loci, IL1A-IL1B, IRF8, and CEBPB-PTPN1, with genome-wide significance (P < 5 × 10(-8)) by direct genotyping and ADO-EGR2 by imputation. We replicated the ADO-EGR2, IRF8, and CEBPB-PTPN1 loci by genotyping 969 Iranian cases and 826 controls. Imputed data in 608 Japanese cases and 737 controls further replicated ADO-EGR2 and IRF8, and meta-analysis additionally identified RIPK2 and LACC1...
February 6, 2017: Nature Genetics
https://www.readbyqxmd.com/read/28165294/bovine-lactoferrin-and-crohn-s-disease-a-case-study
#17
David B Alexander, Masaaki Iigo, Mohamed Abdelgied, Keiji Ozeki, Satoshi Tanida, Takashi Joh, Satoru Takahashi, Hiroyuki Tsuda
A 22-year-old male suffering from abdominal pain, repeated diarrhea, and weight loss visited the Digestive Disease Department of Nagoya City University Hospital on 19 December 2011. He was hospitalized and diagnosed with Crohn's colitis. His Crohn's Disease Activity Index (CDAI) was 415. Treatment by granulocyte apheresis, mesalazine, and adalimumab was started. His CDAI was 314 on 30 December and 215 on 5 January. A colonoscopic examination on 19 January showed almost complete remission in the transverse colon and marked remission in the rectum...
February 2017: Biochemistry and Cell Biology, Biochimie et Biologie Cellulaire
https://www.readbyqxmd.com/read/28164321/dose-de-escalation-to-adalimumab-40-mg-every-3-weeks-in-patients-with-crohn-s-disease-a-nested-case-control-study
#18
S Van Steenbergen, S Bian, S Vermeire, G Van Assche, A Gils, M Ferrante
BACKGROUND: Data on dose de-escalation in patients with Crohn's disease (CD) are limited. AIM: To evaluate outcomes of dose de-escalation from adalimumab (ADM) every other week (EOW) to every three weeks (ETW). METHODS: We selected patients with CD receiving maintenance therapy with ADM 40 mg ETW with serum levels (SL) available before and after dose de-escalation. Sex- and age-matched controls continuing ADM 40 mg EOW were identified. Patient reported outcome, C-reactive protein (CRP) and serum albumin were collected...
February 6, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28147356/infliximab-biosimilar-remsima%C3%A2-in-therapy-of-inflammatory-bowel-diseases-patients-experience-from-one-tertiary-inflammatory-bowel-diseases-centre
#19
M Kolar, D Duricova, M Bortlik, V Hruba, N Machkova, K Mitrova, K Malickova, M Lukas, Milan Lukas
BACKGROUND: The evidence on the efficacy and safety of biosimilar infliximab (IFX) in patients with inflammatory bowel diseases (IBD) is sparse. METHODS: Consecutive IBD patients visiting our centre were included. One cohort composed of prospectively followed patients who were switched from original to biosimilar IFX between January and March 2015. The second cohort included retrospectively assessed anti-tumor necrosis factor α-naïve patients who started therapy between January 2015 and January 2016...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/28146003/comparative-effectiveness-of-mesalamine-sulfasalazine-corticosteroids-and-budesonide-for-the-induction-of-remission-in-crohn-s-disease-a-bayesian-network-meta-analysis
#20
Stephanie Coward, M Ellen Kuenzig, Glen Hazlewood, Fiona Clement, Kerry McBrien, Rebecca Holmes, Remo Panaccione, Subrata Ghosh, Cynthia H Seow, Ali Rezaie, Gilaad G Kaplan
BACKGROUND: Induction treatment of mild-to-moderate Crohn's disease is controversial. PURPOSE: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn's disease. DATA SOURCES: We identified randomized controlled trials from existing Cochrane reviews and an updated literature search in Medline, EMBASE, and CENTRAL to November 2015. STUDY SELECTION: We included randomized controlled trials (n = 22) in adult patients with Crohn's disease that compared budesonide, sulfasalazine, mesalamine, or corticosteroids with placebo or each other, for the induction of remission (8-17 wks)...
January 31, 2017: Inflammatory Bowel Diseases
keyword
keyword
53050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"